Results 31 to 40 of about 27,163 (253)

The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia

Journal of Neuroinflammation, 2021
Background The role of the immune system in stroke is well-recognised. Fingolimod, an immunomodulatory agent licensed for the management of relapsing-remitting multiple sclerosis, has been shown to provide benefit in rodent models of stroke.
Kyle Malone, Andrea C. Diaz Diaz, Jennifer A. Shearer, Anne C. Moore, Christian Waeber   +4 more
doaj   +1 more source

Cardiovascular effects of fingolimod: Relevance, detection and approach

Revista Portuguesa de Cardiologia, 2015
Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial ...
Carlos Aguiar, Sónia Batista, Ricardo Pacheco   +2 more
doaj   +1 more source

The emerging role of FTY720 (Fingolimod) in cancer treatment [PDF]

, 2016
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor.
Abdollahi, Alewijnse, Alexander, Aradhye, Arai, Arlinghaus, Bae, Baumruker, Baxter, Ben-Sasson, Bohler, Bollen, Braun, Brinkmann, Broek, Brune, Brune, Bueno, Bueno, Bueno, Burtin, Byrd, Cabot, Campochiaro, Chauhan, Chen, Chiba, Curino, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cuvillier, Cyster, Cyster, Edwards, Eshhar, Fan, Fan, Fan, Fan, Ferrer, Gajewski, Garcia, Garcia-Foncillas, Garcia-Foncillas, Geilen, Grech, Greten, Habib, Hahn, Hakomori, Hakomori, Hakomori, Han, Han, Hanessian, Hannun, Hannun, He, Hla, Hla, Hla, Hla, Hla, Hla, Hla, Hla, Hla, Hoshino, Huang, Huwiler, Huwiler, Huwiler, Huyton, Ibrahim, Igarashi, Igarashi, Igarashi, Jaffrezou, Kappos, Karliner, Karliner, Kasahara, Katsuoka, Katsuoka, Katsuoka, Kaufmann, Klostergaard, Kohama, Kordula, Kornblau, Lee, Lee, Lei, Lei, Li, Liao, Lichter, Liu, Liu, Liu, Lynch, Lynch, Lynch, Macdonald, Marcucci, Masood, Matsuyama, May, May, Moolenaar, Morisaki, Mosser, Muthusamy, Muthusamy, Muthusamy, Nakamura, Neviani, Neviani, Nozawa, Nozawa, Nussbaumer, Obeid, Obeid, Obeid, Obeid, Oberlies, Odero, Ogretmen, Ohdan, Okumoto, Okuyama, Park, Pchejetski, Pchejetski, Phelps, Pitson, Pitson, Pitson, Pollard, Prior, Proia, Proia, Pyne, Pyne, Pyne, Pyne, Pyne, Pyne, Rader, Radue, Rennard, Rodrigues, Rosen, Rosen, Roy, Ruefli-Brasse, Sabbadini, Sakaguchi, Sanchez, Satoh, Schmouder, Schwartz, Seishima, Sharma, Shinomiya, Shinomiya, Shinomiya, Shinomiya, Shinomiya, Smith, Smith, Song, Song, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Spiegel, Stracke, Stracke, Stracke, Sun, Suzuki, Suzuki, Tagliaferri, Tagliaferri, Takahara, Takuwa, Takuwa, Taniwaki, Tornquist, Troncone, Uesato, Vadas, Vadas, Vadas, Vadas, Verrills, Walsh, Wang, Wang, Wattenberg, Wattenberg, Waxman, Weichselbaum, Wiedermann, Wolf, Wong, Wong, Wood, Woodcock, Wu, Xia, Xia, Xia, Xia, Xu, Xu, Yap, Yee, Yun, Yun, Zangemeister-Wittke, Zawadzke, Zheng, Zheng   +249 more
core   +2 more sources

Effects of fingolimod on heart injury induced by renal ischemia-reperfusion [PDF]

مجله پزشکی دانشگاه علوم پزشکی تبریز
Background. Renal ischemia-reperfusion injury (IRI) is one of the inevitable complications of surgery. The evidence shows that fingolimod, with its anti-inflammatory effects, can play a protective role in renal IRI.
Bahram Niknafs, Yasin Bagheri, Seyyedeh Mina Hejazian, Parya Niknafs, Neda Roshanravan, Mohammadreza Ardalan, Sepideh Zununi Vahed   +6 more
doaj   +1 more source

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study [PDF]

, 2017
Background First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose.
Dechend, Ralf, Haverkamp, Wilhelm [u. v. a.], Limmroth, Volker   +2 more
core   +1 more source

Fingolimod for the treatment of neurological diseases—state of play and future perspectives [PDF]

, 2014
Sphingolipids are a fascinating class of signaling molecules derived from the membrane lipid sphingomyelin. They show abundant expression in the brain.
Rajkumar Vutukuri, Robert Brunkhorst, Waltraud Pfeilschifter   +2 more
core   +2 more sources

Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue? [PDF]

, 2012
Multiple sclerosis (MS) is an inflammatory disorder affecting the brain and spinal cord. Major hallmarks of MS typically include inflammation, demyelination and axon degeneration, although recent studies have also implicated synaptic dysfunction and ...
Brinkmann, Centonze, Cohen, Coleman, Compston, Dutta, Fischer, Hensley, Khatri, Mandolesi, Murray, Papadimitriou, Pitt, Rossi, Smith, Sriram, Wishart, Zhu   +17 more
core   +1 more source

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

BMC Neurology, 2021
Background Fingolimod is a S1P1 receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes.
Silvia Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan   +3 more
doaj   +1 more source

18F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis. [PDF]

, 2020
Brain-infiltrating leukocytes contribute to multiple sclerosis (MS) and autoimmune encephalomyelitis and likely play a role in traumatic brain injury, seizure, and stroke.
Chen, Bao Ying, Clark, Peter M, Ghezzi, Chiara, Quon, Andrew, Radu, Caius G, Villegas, Brendon, Witte, Owen N   +6 more
core   +1 more source

Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]

, 2015
Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core   +1 more source